Open Access

Erratum to: treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice

  • Katherine D LaClair1, 4,
  • Kebreten F Manaye5,
  • Dexter L Lee5,
  • Joanne S Allard5,
  • Alena V Savonenko1, 3,
  • Juan C Troncoso1, 3Email author and
  • Philip C Wong1, 2, 4Email author
Contributed equally
Molecular Neurodegeneration20138:26

https://doi.org/10.1186/1750-1326-8-26

Received: 8 August 2013

Accepted: 8 August 2013

Published: 8 August 2013

The original article was published in Molecular Neurodegeneration 2013 8:18

Correction to LaClair et al.: Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice. Molecular Neurodegeneration 2013 8:18.

After publication of this work [1], we were alerted to an error in the reported cohort size used for the Radial Arm Water Maze as referenced from [2]. The correct cohort size reported in [2] is n=8-13 for each group of mixed gender animals. In addition, it came to our attention that our analysis of a potential false-positive treatment effect caused by gender differences, and therefore bexarotene’s inability to rescue cognitive decline, may appear to be contradicted by the statement that it “was equally effective in both genders” of transgenic mice [2]. However, direct experimental data supporting this statement is not presented. In addition, this statement does not address any differences in the performance of each gender, only that bexarotene appears effective in each gender separately, and the statistical significance of this reported effect remains unknown. Therefore, we maintain that the currently published cognitive preclinical data, including our own, do not validate the potential of bexarotene for Alzheimer’s therapy.”

Notes

Authors’ Affiliations

(1)
Department of Pathology, The Johns Hopkins School of Medicine
(2)
Department of Neuroscience, The Johns Hopkins School of Medicine
(3)
Department of Neurology, The Johns Hopkins School of Medicine
(4)
Program in Cellular and Molecular Medicine, The Johns Hopkins School of Medicine
(5)
Department of Physiology and Biophysics, Howard University College of Medicine

References

  1. LaClair KD, Manaye KF, Lee DL, Allard JS, Savonenko AS, Troncoso JC, Wong PC: Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice. Mol Neurodegener. 2013, 8: 18-10.1186/1750-1326-8-18.PubMed CentralView ArticlePubMedGoogle Scholar
  2. Fitz NF, Cronican AA, Lefterov I, Koldamova R: Comment on “ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science Tech. Comments. 2013, 340: 924-Google Scholar

Copyright

© LaClair et al.; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement